世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

組換え血漿タンパク質の世界市場シェアとランキング、全体売上高と需要予測 2024-2030


Recombinant Plasma Proteins - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

先天性あるいは後天性の重篤な出血性疾患や免疫疾患の治療に不可欠な凝固因子、抗凝固剤、免疫グロブリン、アルブミンなど、広範な治療用タンパク質の供給源は、ほぼ50年間、ヒト血漿の分画しかなかった。この20... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年3月1日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

先天性あるいは後天性の重篤な出血性疾患や免疫疾患の治療に不可欠な凝固因子、抗凝固剤、免疫グロブリン、アルブミンなど、広範な治療用タンパク質の供給源は、ほぼ50年間、ヒト血漿の分画しかなかった。この20年間で、哺乳類細胞培養への組換え技術の応用により、生産性、コスト、免疫原性リスクにおいていくつかの制約はあるものの、組換え技術が可能になった。
組換え血漿タンパク質の世界市場は、2023年には9,200万米ドルと推定され、2024-2030年の予測期間中のCAGRは2.1%で、2030年には1億640万米ドルに再調整されると予測されている。

当社の調査によると、医療機器の世界市場は2023年に6,030億米ドルと推定され、今後6年間は年平均成長率5%で成長する。世界の医療支出は世界GDPの10%を占め、高齢化による健康ニーズの増加、慢性疾患や感染症の流行、新興市場の拡大により、近年増加の一途をたどっている。医療機器市場は、ヘルスケア産業において重要な役割を果たしている。この市場を牽引しているのは、世界的な高度医療サービスに対する需要の高まり、医療技術の進歩、高齢者人口の増加、医療費の増加、病気の早期診断・治療に対する意識の高まりなど、いくつかの要因である。

レポートの範囲
本レポートは、組換え血漿タンパク質の世界市場を包括的に紹介することを目的としており、総売上高、主要企業の市場シェアおよびランキングに焦点を当て、地域別・国別、タイプ別、用途別の組換え血漿タンパク質の分析も併せて掲載しています。
組換え血漿タンパク質の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量分析および定性分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、組換え血漿タンパク質に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
CSL社
シャイアー(武田薬品工業)
オクタファーマ
ノボ ノルディスク
バイエル
バイオベラティブ・セラピューティクス社(サノフィ)
アプテボ・セラピューティクス
ファーミンググループ
ファイザー
タイプ別セグメント
チャイニーズハムスター卵巣(CHO)細胞株
ベビーハムスター腎臓(BHK)細胞株
ヒト胚性腎臓(HEK)細胞株
その他
用途別セグメント
血友病A
血友病B
フォンウィルブランド病
その他
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

各章の概要
第1章:報告書のスコープ、世界の総市場規模を紹介します。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:組換え血漿蛋白質メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章:組換え血漿タンパク質の地域レベルでの収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章 組換え血漿タンパク質の国別売上高各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Recombinant Plasma Proteins Product Introduction
1.2 Global Recombinant Plasma Proteins Market Size Forecast
1.3 Recombinant Plasma Proteins Market Trends & Drivers
1.3.1 Recombinant Plasma Proteins Industry Trends
1.3.2 Recombinant Plasma Proteins Market Drivers & Opportunity
1.3.3 Recombinant Plasma Proteins Market Challenges
1.3.4 Recombinant Plasma Proteins Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Plasma Proteins Players Revenue Ranking (2023)
2.2 Global Recombinant Plasma Proteins Revenue by Company (2019-2024)
2.3 Key Companies Recombinant Plasma Proteins Manufacturing Base Distribution and Headquarters
2.4 Key Companies Recombinant Plasma Proteins Product Offered
2.5 Key Companies Time to Begin Mass Production of Recombinant Plasma Proteins
2.6 Recombinant Plasma Proteins Market Competitive Analysis
2.6.1 Recombinant Plasma Proteins Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Recombinant Plasma Proteins Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Proteins as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chinese Hamster Ovary (CHO) Cell Line
3.1.2 Baby Hamster Kidney (BHK) Cell Line
3.1.3 Human Embryonic Kidney (HEK) Cell Line
3.1.4 Others
3.2 Global Recombinant Plasma Proteins Sales Value by Type
3.2.1 Global Recombinant Plasma Proteins Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Plasma Proteins Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Plasma Proteins Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hemophilia A
4.1.2 Hemophilia B
4.1.3 Von Willebrand Disease
4.1.4 Others
4.2 Global Recombinant Plasma Proteins Sales Value by Application
4.2.1 Global Recombinant Plasma Proteins Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Plasma Proteins Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Plasma Proteins Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Plasma Proteins Sales Value by Region
5.1.1 Global Recombinant Plasma Proteins Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Plasma Proteins Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Plasma Proteins Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Plasma Proteins Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Recombinant Plasma Proteins Sales Value, 2019-2030
5.2.2 North America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030
5.3.2 Europe Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Recombinant Plasma Proteins Sales Value, 2019-2030
5.4.2 Asia Pacific Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Recombinant Plasma Proteins Sales Value, 2019-2030
5.5.2 South America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Recombinant Plasma Proteins Sales Value, 2019-2030
5.6.2 Middle East & Africa Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Plasma Proteins Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Plasma Proteins Sales Value
6.3 United States
6.3.1 United States Recombinant Plasma Proteins Sales Value, 2019-2030
6.3.2 United States Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030
6.4.2 Europe Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Plasma Proteins Sales Value, 2019-2030
6.5.2 China Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Plasma Proteins Sales Value, 2019-2030
6.6.2 Japan Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Plasma Proteins Sales Value, 2019-2030
6.7.2 South Korea Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Plasma Proteins Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Plasma Proteins Sales Value, 2019-2030
6.9.2 India Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 CSL Limited
7.1.1 CSL Limited Profile
7.1.2 CSL Limited Main Business
7.1.3 CSL Limited Recombinant Plasma Proteins Products, Services and Solutions
7.1.4 CSL Limited Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.1.5 CSL Limited Recent Developments
7.2 Shire (Takeda Pharmaceutical Company Limited)
7.2.1 Shire (Takeda Pharmaceutical Company Limited) Profile
7.2.2 Shire (Takeda Pharmaceutical Company Limited) Main Business
7.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Products, Services and Solutions
7.2.4 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
7.3 Octapharma
7.3.1 Octapharma Profile
7.3.2 Octapharma Main Business
7.3.3 Octapharma Recombinant Plasma Proteins Products, Services and Solutions
7.3.4 Octapharma Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.3.5 Novo Nordisk Recent Developments
7.4 Novo Nordisk
7.4.1 Novo Nordisk Profile
7.4.2 Novo Nordisk Main Business
7.4.3 Novo Nordisk Recombinant Plasma Proteins Products, Services and Solutions
7.4.4 Novo Nordisk Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.4.5 Novo Nordisk Recent Developments
7.5 Bayer
7.5.1 Bayer Profile
7.5.2 Bayer Main Business
7.5.3 Bayer Recombinant Plasma Proteins Products, Services and Solutions
7.5.4 Bayer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.5.5 Bayer Recent Developments
7.6 Bioverativ Therapeutics, Inc. (Sanofi)
7.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Profile
7.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Main Business
7.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Products, Services and Solutions
7.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Developments
7.7 Aptevo Therapeutics
7.7.1 Aptevo Therapeutics Profile
7.7.2 Aptevo Therapeutics Main Business
7.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Products, Services and Solutions
7.7.4 Aptevo Therapeutics Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.7.5 Aptevo Therapeutics Recent Developments
7.8 Pharming Group
7.8.1 Pharming Group Profile
7.8.2 Pharming Group Main Business
7.8.3 Pharming Group Recombinant Plasma Proteins Products, Services and Solutions
7.8.4 Pharming Group Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.8.5 Pharming Group Recent Developments
7.9 Pfizer
7.9.1 Pfizer Profile
7.9.2 Pfizer Main Business
7.9.3 Pfizer Recombinant Plasma Proteins Products, Services and Solutions
7.9.4 Pfizer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.9.5 Pfizer Recent Developments
8 Industry Chain Analysis
8.1 Recombinant Plasma Proteins Industrial Chain
8.2 Recombinant Plasma Proteins Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Plasma Proteins Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Plasma Proteins Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
The global market for Recombinant Plasma Proteins was estimated to be worth US$ 92 million in 2023 and is forecast to a readjusted size of US$ 106.4 million by 2030 with a CAGR of 2.1% during the forecast period 2024-2030

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Plasma Proteins, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Recombinant Plasma Proteins by region & country, by Type, and by Application.
The Recombinant Plasma Proteins market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Plasma Proteins.

Market Segmentation
By Company
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Segment by Type:
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Plasma Proteins manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Recombinant Plasma Proteins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Recombinant Plasma Proteins in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Recombinant Plasma Proteins Product Introduction
1.2 Global Recombinant Plasma Proteins Market Size Forecast
1.3 Recombinant Plasma Proteins Market Trends & Drivers
1.3.1 Recombinant Plasma Proteins Industry Trends
1.3.2 Recombinant Plasma Proteins Market Drivers & Opportunity
1.3.3 Recombinant Plasma Proteins Market Challenges
1.3.4 Recombinant Plasma Proteins Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Plasma Proteins Players Revenue Ranking (2023)
2.2 Global Recombinant Plasma Proteins Revenue by Company (2019-2024)
2.3 Key Companies Recombinant Plasma Proteins Manufacturing Base Distribution and Headquarters
2.4 Key Companies Recombinant Plasma Proteins Product Offered
2.5 Key Companies Time to Begin Mass Production of Recombinant Plasma Proteins
2.6 Recombinant Plasma Proteins Market Competitive Analysis
2.6.1 Recombinant Plasma Proteins Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Recombinant Plasma Proteins Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Proteins as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chinese Hamster Ovary (CHO) Cell Line
3.1.2 Baby Hamster Kidney (BHK) Cell Line
3.1.3 Human Embryonic Kidney (HEK) Cell Line
3.1.4 Others
3.2 Global Recombinant Plasma Proteins Sales Value by Type
3.2.1 Global Recombinant Plasma Proteins Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Plasma Proteins Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Plasma Proteins Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hemophilia A
4.1.2 Hemophilia B
4.1.3 Von Willebrand Disease
4.1.4 Others
4.2 Global Recombinant Plasma Proteins Sales Value by Application
4.2.1 Global Recombinant Plasma Proteins Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Plasma Proteins Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Plasma Proteins Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Plasma Proteins Sales Value by Region
5.1.1 Global Recombinant Plasma Proteins Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Plasma Proteins Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Plasma Proteins Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Plasma Proteins Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Recombinant Plasma Proteins Sales Value, 2019-2030
5.2.2 North America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030
5.3.2 Europe Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Recombinant Plasma Proteins Sales Value, 2019-2030
5.4.2 Asia Pacific Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Recombinant Plasma Proteins Sales Value, 2019-2030
5.5.2 South America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Recombinant Plasma Proteins Sales Value, 2019-2030
5.6.2 Middle East & Africa Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Plasma Proteins Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Plasma Proteins Sales Value
6.3 United States
6.3.1 United States Recombinant Plasma Proteins Sales Value, 2019-2030
6.3.2 United States Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030
6.4.2 Europe Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Plasma Proteins Sales Value, 2019-2030
6.5.2 China Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Plasma Proteins Sales Value, 2019-2030
6.6.2 Japan Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Plasma Proteins Sales Value, 2019-2030
6.7.2 South Korea Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Plasma Proteins Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Plasma Proteins Sales Value, 2019-2030
6.9.2 India Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 CSL Limited
7.1.1 CSL Limited Profile
7.1.2 CSL Limited Main Business
7.1.3 CSL Limited Recombinant Plasma Proteins Products, Services and Solutions
7.1.4 CSL Limited Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.1.5 CSL Limited Recent Developments
7.2 Shire (Takeda Pharmaceutical Company Limited)
7.2.1 Shire (Takeda Pharmaceutical Company Limited) Profile
7.2.2 Shire (Takeda Pharmaceutical Company Limited) Main Business
7.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Products, Services and Solutions
7.2.4 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
7.3 Octapharma
7.3.1 Octapharma Profile
7.3.2 Octapharma Main Business
7.3.3 Octapharma Recombinant Plasma Proteins Products, Services and Solutions
7.3.4 Octapharma Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.3.5 Novo Nordisk Recent Developments
7.4 Novo Nordisk
7.4.1 Novo Nordisk Profile
7.4.2 Novo Nordisk Main Business
7.4.3 Novo Nordisk Recombinant Plasma Proteins Products, Services and Solutions
7.4.4 Novo Nordisk Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.4.5 Novo Nordisk Recent Developments
7.5 Bayer
7.5.1 Bayer Profile
7.5.2 Bayer Main Business
7.5.3 Bayer Recombinant Plasma Proteins Products, Services and Solutions
7.5.4 Bayer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.5.5 Bayer Recent Developments
7.6 Bioverativ Therapeutics, Inc. (Sanofi)
7.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Profile
7.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Main Business
7.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Products, Services and Solutions
7.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Developments
7.7 Aptevo Therapeutics
7.7.1 Aptevo Therapeutics Profile
7.7.2 Aptevo Therapeutics Main Business
7.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Products, Services and Solutions
7.7.4 Aptevo Therapeutics Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.7.5 Aptevo Therapeutics Recent Developments
7.8 Pharming Group
7.8.1 Pharming Group Profile
7.8.2 Pharming Group Main Business
7.8.3 Pharming Group Recombinant Plasma Proteins Products, Services and Solutions
7.8.4 Pharming Group Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.8.5 Pharming Group Recent Developments
7.9 Pfizer
7.9.1 Pfizer Profile
7.9.2 Pfizer Main Business
7.9.3 Pfizer Recombinant Plasma Proteins Products, Services and Solutions
7.9.4 Pfizer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024)
7.9.5 Pfizer Recent Developments
8 Industry Chain Analysis
8.1 Recombinant Plasma Proteins Industrial Chain
8.2 Recombinant Plasma Proteins Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Plasma Proteins Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Plasma Proteins Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る